Previous 10 | Next 10 |
2024-05-15 10:01:12 ET More on Health Care Select Sector SPDR XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care Health care is still very crowded but trades at a discount vs. history - BofA Health ca...
2024-05-15 09:25:53 ET Gainers: SINTX Technologies ( SINT ) +186% . Faraday Future Intelligent Electric ( FFIE ) +82% . Edible Garden AG EDBL +82% after Q1 earnings release . AERWINS Technologies ( AWIN ) +33% . Greenwave Technology Solu...
RESEARCH TRIANGLE PARK, N.C., May 14, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX) today announced that new data on oral, once-daily ORLADEYO ® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) will be presented at the European Academy ...
RESEARCH TRIANGLE PARK, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Federal Commission for Protection against Health Risks (COFEPRIS) in Mexico has granted approval for oral, once-daily ORLADEYO ® (berotralstat) f...
RESEARCH TRIANGLE PARK, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO ® (berotralstat) demonstrating that patients with hereditary angioedema (HAE) in the Unite...
2024-05-07 06:15:31 ET Summary BioCryst reported strong earnings with top and bottom line beats. Its success reflects positive performance by its approved ORLADEYO. ORLADEYO's $1 billion peak sales potential coupled with BioCryst's <$1 billion market cap makes it a speculat...
2024-05-06 18:47:50 ET For the most part, U.S. stocks had a good Monday, with the bellwether S&P 500 index confidently marching more than 1% higher. But BioCryst Pharmaceuticals (NASDAQ: BCRX) and its investors had a really good day, as the company delivered a first quar...
2024-05-06 13:00:26 ET Image source: The Motley Fool. BioCryst Pharmaceuticals (NASDAQ: BCRX) Q1 2024 Earnings Call May 06, 2024 , 8:30 a.m. ET Operator Continue reading For further details see: BioCryst Pharmaceuticals (BCRX) Q1 2024 Earnings...
2024-05-06 11:42:16 ET BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2024 Earnings Call Transcript May 06, 2024, 08:30 AM ET Company Participants John Bluth - IR Jon Stonehouse - CEO Charlie Gayer - CCO Helen Thackray - Chief R&D Officer Anthony Doyle - CF...
2024-05-06 10:36:37 ET More on BioCryst Pharmaceuticals BioCryst Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation BioCryst's Revenue Gains Offset By Rising Expenses: A Closer Look BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2023 Earnings Call Transcr...
News, Short Squeeze, Breakout and More Instantly...
BioCryst Pharmaceuticals Inc. Company Name:
BCRX Stock Symbol:
NASDAQ Market:
BioCryst Pharmaceuticals Inc. Website:
RESEARCH TRIANGLE PARK, N.C., July 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2024 financial results on Monday, August 5, 2024. BioCryst management will host a conference call and webcast ...
RESEARCH TRIANGLE PARK, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru has granted approval for oral, once-daily ORLADEYO ® (berotralstat) for t...
2024-06-27 04:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...